Discovery of (R)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class dual pharmacology multivalent muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

Journal of Medicinal Chemistry

Volumn 58, Issue 6, 2015, Pages 2609-2622

  Hughes, Adam D ^a   Chen, Yan ^a   Hegde, Sharath S ^a   Jasper, Jeffrey R ^a   Jaw Tsai, Sarah ^a   Lee, Tae Weon ^a   McNamara, Alexander ^a   Pulido Rios, M Teresa ^a   Steinfeld, Tod ^a   Mammen, Mathai ^a  

^a THERAVANCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 [[2 CHLORO 4 [[[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]METHYL] 3 METHOXYPHENYL]AMINO] 3 OXOPROPYL]PIPERIDIN 4 YL[1,1' BIPHENYL] 2 YLCARBAMATE; 1 [3 [[3 CHLORO 4 [[[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]METHYL]PHENYL]AMINO 3 OXOPROPYL]PIPERIDIN 4 YL[1,1' BIPHENYL] 2 YLCARBAMATE; 1 [3 [[4 [[[ 2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]METHYL]CYCLOHEXYL]AMINO] 3 OXOPROPYL]PIPERIDIN 4 YL[1,1' BIPHENYL] 2 YLCARBAMATE; 1 [3 [[4 [[[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO)METHYL] 3 METHYLPHENYL]AMINO 3 OXOPROPYL]PIPERIDIN 4 YL [1,1' BIPHENYL] 2 YLCARBAMATE; 1 [3 [[4 [[[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]METHYL] 2 METHOXYPHENYL]AMINO] 3 OXOPROPYL]PIPERIDIN 4 YL [1,1' BIPHENYL] 2 YLCARBAMATE; 1 [3 [[4 [[[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]METHYL] 2 METHYLPHENYL]AMINO[ 3 OXOPROPYL]PIPERIDIN 4 YL [1,1' BIPHENYL] 2 YLCARBAMATE; 1 [3 [[4 [[[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]METHYL] 3 METHOXY 2 METHYLPHENYL]AMINO] 3 OXOPROPYL] PIPERIDIN 4 YL [1,1' BIPHENYL] 2 YLCARBAMATE; 1 [3 [[4 [[[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]METHYL] 5 METHOXY 2 METHYLPHENYL]AMINO] 3 OXOPROPYL] PIPERIDIN 4 YL; 1 [3 [[4 [[[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]METHYL]PHENYL]AMINO] 3 OXOPROPYL]PIPERIDIN 4 YL[1,1' BIPHNEYL] 2 YLCARBAMATE; 1 [3 [[4 [[[2 HYDROXY 2 [8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]METHYL] 3 METHOXYPHENYL]AMINO] 3 OXOPROPYL]PIPERIDIN 4 YL [1,1' BIPHENYL] 2 YLCARBAMATE; 1 [3 [[5 [[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5YL)ETHYL]AMINO]PENTYL]AMINO] 3 OXOPROPYL]PIPERIDIN 4 YL [1,1' BIPHENYL] 2 YLCARBAMATE; 1 [9 [[2 HYDROXY 2 (8 HYDROXY 2 OXO 1,2 DIHYDROQUINOLIN 5 YL)ETHYL]AMINO]NONYL]PIPERIDIN 4 YL [1,1' BIPHENYL] 2 YLCARBAMATE; BATEFENTEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALMETEROL; UNCLASSIFIED DRUG; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBAMIC ACID DERIVATIVE; GSK961081; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; FORCED EXPIRATORY VOLUME; GUINEA PIG; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG DEVELOPMENT; DRUG EFFECTS; HEK293 CELL LINE; INHALATIONAL DRUG ADMINISTRATION; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; CARBAMATES; CHO CELLS; CRICETULUS; DRUG DISCOVERY; GUINEA PIGS; HEK293 CELLS; HUMANS; LUNG; MODELS, MOLECULAR; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 84925967778     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501915g     Document Type: Article

References (32)

1. Vestbo, J.; Hurd, S. S.; Agusti, A. G.; Jones, P. W.; Vogelmeier, C.; Anzueto, A.; Barnes, P. J.; Fabbri, L. M.; Martinez, F. J.; Nishimura, M.; Stockley, R. A.; Sin, D. D.; Rodriguez-Roisin, R. Global strategy for the diagosis, management, and prevention of chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 2013, 187 (4) 347-365
2. Toy, E. L.; Beaulieu, N. U.; McHale, J. M.; Welland, T. R.; Plauschinat, C. A.; Swensen, A.; Duh, M. S. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs Respir. Med. 2011, 105, 435-441
3. van Noord, J. A.; Buhl, R.; Laforce, C.; Martin, C.; Jones, F.; Dolker, M.; Overend, T. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease Thorax 2010, 65, 1086-1091
4. Donohue, J. F.; Maleki-Yazdi, M. R.; Kilbride, S.; Mehta, R.; Kalberg, C.; Church, A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD Respir. Med. 2013, 107, 1538-46
5. For example, Prosonix, http://www.prosonix.co.uk/; Pearl Therapeutics, http://www.pearltherapeutics.com/; and Pulmatrix, http://www.pulmatrix.com/ (all accessed February 2014).
6. 2-agonists and muscarinic antagonists in COPD Pulm. Pharmacol. Ther. 2010, 23, 257-267
7. Cooper, A. E.; Ferguson, D.; Grime, K. Optimisation of DMPK by the inhaled route: challenges and approaches Curr. Drug Metab. 2012, 13 (4) 457-473
8. 2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach J. Med. Chem. 2010, 53, 4522-4530
9. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48 (21) 6523-6543
10. Hughes, A. D.; Chin, K. H.; Dunham, S. L.; Jasper, J. R.; King, K. E.; Lee, T. W.; Mammen, M.; Martin, J.; Steinfeld, T. Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules Bioorg. Med. Chem. Lett. 2011, 21, 1354-1358
11. Hughes, A. D. Discovery of muscarinic acetylcholine receptor antagonist and beta-2 adrenoceptor agonist (MABA) dual pharmacology molecules. In RDD Europe 2013; Dalby, R. N.; Byron, P. R.; Peart, J.; Suman, J. D.; Young, P. M.; Traini, D., Eds.; Virginia Commonwealth University: Richmond, VA, 2013; Vol, 1, pp 47-58.
12. Chao, R.; Rapta, M.; Colson, P.-J.; Lee, J. Crystalline form of a biphenyl compound. 20050182092, February 11, 2005; Theravance, Inc., USA.
13. Chao, R.; Rapta, M.; Colson, P.-J. Crystalline form of a biphenyl compound. U.S. Patent 7,521,558, 2009.
14. Ritchie, T. J.; Luscombe, C. N.; Macdonald, S. J. F. Analysis of the calculated physicochemical properties of respiratory drugs: Can we design for inhaled drugs yet? J. Chem. Inf. Model. 2009, 49, 1025-1032
15. Mundy, C.; Kirkpatrick, P. Tiotropium bromide Nat. Rev. Drug Discovery 2004, 3, 643-644
16. 3 receptor J. Med. Chem. 2013, 56, 8746-8756
17. Sykes, D. A.; Dowling, M. R.; Leighton-Davies, J.; Kent, T. C.; Fawcett, L.; Renard, E.; Trifilieff, A.; Charlton, S. J. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium J. Pharmacol. Exp. Ther. 2012, 343 (2) 520-528
18. McNamara, A.; Pulido-Rios, M. T.; Hegde, S. S.; Martin, W. J. Application of the classical Einthoven model of bronchoconstriction to the study of inhaled bronchodilators in rodents Pharmacol. Toxicol. Methods 2011, 63, 89-95
19. Revill, P.; Serradell, N.; Bolos, J.; Bayes, M. Arformoterol tartrate Drugs Future 2006, 31, 944
20. Spina, D. Current and novel bronchodilators in respiratory disease Curr. Opin. Pulm. Med. 2014, 20 (1) 73-86
21. Pulido-Rios, M. T.; McNamara, A.; Obedencio, G. P.; Ji, Y.; Jaw-Tsai, S.; Martin, W. J.; Hegde, S. S. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models J. Pharmacol. Exp. Ther. 2013, 346, 241-250
22. https://www.spiriva.com (accessed February 2014).
23. Chao, R. S.; Rapta, M.; Colson, P.-J. Crystalline form of a biphenyl compound. 2005029013, March 2, 2006; Theravance, Inc, USA.
24. Vauquelin, G.; Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action Br. J. Pharmacol. 2010, 161, 488-508
25. Hughes, A. D.; McNamara, A.; Steinfeld, T. Multivalent dual pharmacology muscarinic antagonist and β2 agonist (MABA) molecules for the treatment of COPD Prog. Med. Chem. 2012, 51, 71-95
26. 2 adrenoceptor agonist (MABA) properties J. Pharmacol. Exp. Ther. 2014, 351 (1) 190-199
27. Bateman, E. D.; Kornmann, O.; Ambery, C.; Norris, V. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD Pulm. Pharmacol. Ther. 2013, 26, 581-587
28. Wielders, P. L.; Ludwig-Senqpiel, A.; Locantore, N.; Baggen, S.; Chan, R.; Riley, J. H. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081 Eur. Respir. J. 2013, 42, 972-981
29. 2 adrenoceptor Nature 2011, 469, 175-181
30. Molecular Operating Environment (MOE), version 2013.10; Chemical Computing Group Inc.: Montreal, Quebec, Canada; http://www.chemcomp.com/ (accessed February 2014).
31. Pera, T.; Penn, R. B. Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway Curr. Opin. Pharmacol. 2014, 16, 72-81
32. Mammen, M.; Dunham, S.; Hughes, A. D.; Lee, T. W.; Husfeld, C.; Stangeland, E. Biphenyl derivatives. 2004167167, August 26, 2004; Theravance, Inc., USA.